SUBSCRIBERS
FDA approves another in a new class of cholesterol drugs
Amgen's Repatha joins Sanofi's Praluent; but potency of medications raises a key question
Add BT as a preferred sourcePublished Sun, Aug 30, 2015 · 09:50 PM
New York
THE US Food and Drug Administration (FDA) has approved the second drug in a novel class of powerful cholesterol-lowering medications.
The new drug, Repatha, made by Amgen, is intended for people with extremely high cholesterol levels and those with heart disease who cannot sufficiently lower their cholesterol levels with statins and other therapies. Repatha will cost US$14,100 per year.
Share with us your feedback on BT's products and services
